TS
AMLX icon

Thomas Steyer’s Amylyx Pharmaceuticals AMLX Stock Holding History

Thomas Steyer’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,150,221
Closed -$3.73M – 153
2024
Q3 		$3.73M Hold
1,150,221
– – 0.02% 96
2024
Q2 		$2.19M Hold
1,150,221
– – 0.01% 102
2024
Q1 		$3.27M Buy
+1,150,221
New +$15M 0.01% 106

Other funds holding AMLX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Thomas Steyer's AMLX Position: Q4 2024 in Review

Thomas Steyer sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2024, closing a stake of 1,150,221 shares — an estimated $3.73M sold.

Thomas Steyer first reported a position in AMLX in Q1 2024 and held it in 3 quarters. The position peaked at $3.73M in Q3 2024. 122 funds tracked by Wall St. Rank hold AMLX as of Q4 2024.

  • Thomas Steyer reported no remaining Amylyx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Thomas Steyer sold 1,150,221 Amylyx Pharmaceuticals shares in Q4 2024, an estimated $3.73M.
  • Thomas Steyer first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Thomas Steyer's Amylyx Pharmaceuticals position peaked at $3.73M in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2024.

Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.